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Background: Osteoinduction and proliferation of bone-marrow stromal cells (BMSCs) in three-dimensional (3D)
poly(ε-caprolactone) (PCL) scaffolds have not been studied throughly and are technically challenging. This
study aimed to optimize nanocomposites of 3D PCL scaffolds to provide superior adhesion, proliferation and
differentiation environment for BMSCs in this scenario.
Methods: BMSCs were isolated and cultured in a novel 3D tissue culture poly(ε-caprolactone) (PCL) scaffold coated
with poly-lysine, hydroxyapatite (HAp), collagen and HAp/collagen. Cell morphology was observed and BMSC
biomarkers for osteogenesis, osteoblast differentiation and activation were analyzed.
Results: Scanning Electron Microscope (SEM) micrographs showed that coating materials were uniformly deposited
on the surface of PCL scaffolds and BMSCs grew and aggregated to form clusters during 3D culture. Both mRNA and
protein levels of the key players of osteogenesis and osteoblast differentiation and activation, including runt-related
transcription factor 2 (Runx2), alkaline phosphates (ALP), osterix, osteocalcin, and RANKL, were significantly higher in
BMSCs seeded in PCL scaffolds coated with HAp or HAp/collagen than those seeded in uncoated PCL scaffolds,
whereas the expression levels were not significantly different in collagen or poly-lysine coated PCL scaffolds. In addition,
poly-lysine, collagen, HAp/collagen, and HAp coated PCL scaffolds had significantly more viable cells than uncoated
PCL scaffolds, especially scaffolds with HAp/collagen and collagen-alone coatings. That BMSCs in HAp or HAp/collagen
PCL scaffolds had remarkably higher ALP activities than those in collagen-coated alone or uncoated PCL scaffolds
indicating higher osteogenic differentiation levels of BMSCs in HAp or HAp/collagen PCL scaffolds. Moreover,
morphological changes of BMSCs after four-week of 3D culture confirmed that BMSCs successfully differentiated
into osteoblast with spread-out phenotype in HAp/collagen coated PCL scaffolds.
Conclusion: This study showed a proof of concept for preparing biomimetic 3D poly (ε-caprolactone)/
hydroxyapatite/collagen scaffolds with excellent osteoinduction and proliferation capacity for bone regeneration.
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Bone consists mainly of collagen fibres and an inor-
ganic bone mineral in the form of small crystals [1].
The main constituents of human bones are bone min-
eral (~60–70 wt%), collagen (~10–30 wt%) and water
(~10-20 wt%) [2-5]. Most of the rest is collagen, and
bone also contains a small amount of other proteins
and inorganic salts [6]. As a renewable tissue, it can
spontaneously repair its slight loss or minor damages
by regenerating [7,8]. However, treatment of large seg-
mental bone defects, which often involves bone repair
or replacement, remains as an unsolved medical chal-
lenge for clinicians and researchers [9,10]. Bone dis-
eases including osteogenesis imperfecta, osteoarthritis,
osteomyelitis, paralleled with fractures and traumas, as
well as tumor resection can all lead to large segmental
bone defects [11]. The grafts which are necessary for
the treatment of large scale bone defects often include
autografts, allografts, xenografts and synthetic biomaterial
scaffolds. However, because autografts are not sufficiently
available, as well as allografts and xenografts have risks of
disease transmission or adverse host immune responses
[12], it is urgent to develop bone substitution materials by
using synthetic biomaterial scaffolds. Biomedical scaffolds
have been adopted to restore function and damage in
human tissues and are often used in tissue engineering as
a physical and biological support for tissue regeneration
[9,13-17].
Development of scaffold materials for use in bone
tissue engineering (BTE) that mimic both the structure
and mechanical properties of the natural bone still re-
mains unmet needs for scientists [9,13,15,18]. Scaffolds
should provide a highly porous matrix with intercon-
nected pores that allow the exchange of nutrients, oxy-
gen and metabolic waste products [18]. The synthetic
biomaterial scaffolds should provide an initial platform
for cells to retain in the defects, support cell growth, and
maintain phenotypes [16,19]. An ideal scaffold for BTE
should allow cell adhesion, migration, proliferation and
differentiation by carrying growth factors and other
factors [8,20].
Recently, three-dimensional (3D) fabricated scaffolds
have been considered one of the most promising mate-
rials in BTE because of their highly precise pore size,
structure, interconnectivity, and mechanical properties
[21-24]. Among these scaffolds, biodegradable polymer-
based 3D scaffolds have attracted much attention in
recent decades, such as poly(lactic acid) (PLA), poly(gly-
colic acid) (PGA), poly(ε-caprolactone) (PCL), or their
random copolymer poly(lactic acid-co-glycolic acid)
(PLGA) [25-31]. PCL has favorable characteristics of good
biocompatibility and minimal inflammation and has been
used in many FDA (Food and Drug Administration) ap-
proved implants, including drug delivery devices, adhesionbarriers, suture materials, and etc. [32]. The PCL freeform
fabrication has also been widely used in the fabrication of
porous 3D scaffolds for BTE research [15,33].
HAp and collagen are both considered to be biomim-
etic and they are both components of natural bones. In
BTE, HAp, a major inorganic component in natural
bone, has been often used due to its high mechanical
strength, osteoinductivity, and excellent biocompatibility
[34,35]. HAp is believed to stimulate the formation, pre-
cipitation, and deposition of calcium phosphate from
simulated body fluid, resulting in enhanced bone-matrix
interface strength. The addition of HAp to polymer scaf-
folds has been shown to improve the bioactivity and
mechanical properties and to potentially reduce adverse
effects associated with the degradation of some synthetic
polymer [13,36-39], such as PLLA (poly-l-lactide acid),
PLGA, PMMA (Poly(methyl methacrylate)), etc. Likewise,
it was reported that collagen coating promoted bone cell
proliferation, improved cell adhesion and enhanced osteo-
genic cell differentiation [40,41]. More importantly, the
initial adhesion of periosteum segments was greatly
improved by collagen-coating, which thus facilitated cell
outgrowth and handling efficiency on implantation [42].
At the same time, poly-lysine is often used to enhance
cell binding by increasing electrostatic interaction be-
tween negatively-charged ions of the cell membrane and
positively-charged surface ions of attachment factors on
the culture surface. When adsorbed to the culture sur-
face, it increases the number of positively-charged sites
available for cell binding.
Our current study was designed to evaluate the
osteoinduction capacity of 3D PCL scaffold for potential
treatment of large segmental bone defects and further
optimization by coating with poly-lysine, HAp, collagen
or HAp/collagen to form favorable nanocomposites. To
do so, bone-marrow derived stromal cells (BMSCs) were
cultured in 3D PCL matrix. BMSCs exhibit multiple
traits of a stem cell population. They have significant
proliferative capacity and can be greatly expanded
in vitro and induced to differentiate into multiple cell
types. Under certain conditions, BMSCs are demonstrated
to be osteogenic on biomaterials without addition of any
other factors and have capacity to grow multiplicatively
for a longer passage number than differentiated cells
[43,44]. In summary, our goal is to design and optimize a
precisely controlled 3D lattice that facilitates the attach-
ment, survival, migration, proliferation, and differentiation
of BMSCs and promotes a bone healing response. The re-
sults can be potentially utilized to the treatment of large
segmental bone defects.
Materials and methods
3D Biotech PCL scaffolds, Type I Collagen of calf skin,
HAp, poly (L-Lysine), and β-actin antibody were purchased
Wang et al. Journal of Translational Medicine  (2015) 13:152 Page 3 of 11from Sigma-Aldrich, Runx2, and RANKL antibodies
were purchased from Cell Signaling Technologies,
Osteocalcin antibody was purchased from Santa Cruz,
and Osterix and ALP antibodies were purchased from
Abcam. All chemicals except indicated ones were pur-
chased from Sinopharm Chemical Reagent Co (Shanghai,
China). PCL scaffolds were immersed in 75% alcohol over-
night before use.
Surface with collagen coating
A collagen coating was completed by immersing the
PCL scaffolds into a collagen solution (10 mg/mL and
30 mg/mL in 0.05 M acetic acid as indicated) overnight.
Afterwards, the constructs were washed quickly three
times with PBS (Phosphate Buffered Saline) and kept
air-dried. Before cell seeding, the scaffolds were balanced
with medium, and medium was changed three times.
Surface with HAp coating
HAp powders with 15% of weight percentage relative to
PCL was added into 2 ml THF/DMF (1/1 volume ratio).
The mixture was sonicated for 1 hour and added to PCL
scaffolds. The coating was completed by immersing the
PCL scaffolds into HAp solution for 1 h. Afterwards,
The scaffolds were immediately frozen in liquid nitro-
gen. Solvent extraction was performed in cold ethanol at
−20°C; ethanol was changed three times. Afterwards, the
constructs were washed quickly three times with PBS
and kept air-dried. Then the scaffolds were subjected for
medium balancing and cell seeding.
Surface with HAp and collagen coating
PCL scaffolds were first coated with HAp as described,
and then were coated with collagen as indicated. After-
wards, the constructs were washed quickly three times
with PBS and kept air-dried. Medium balancing and cell
seeding follow.
Surface with poly-L-lysine coating
PCL scaffolds were immersed in 0.01% (W/V) poly-
lysine water solution. After 3 hours, the solution was re-
moved through aspiration and the scaffolds were rinsed
thoroughly. PCL scaffolds were dried for two hours be-
fore the scaffolds were balanced with medium. And
medium was changed three times before cell seeding.
Isolation and expansion of BMSCs
The use of rats and all related procedures in this study
were approved by Shanghai Jiao Tong University Affili-
ated Sixth’s People’s Hospital Animal Care and Use
Committee. All rats were provided with sterilized food
and water and housed in a barrier facility under a
12-hour light/dark cycle. As previously described, the
bone-marrow samples were incubated in isolation medium(25 mM HEPES, 128.5 mM NaCl, 5.4 mM KCl, 5.5 mM
D(+)-glucose, 51.8 mM D(+)-saccharose, 0.1% bovine
serum albumin (Sigma, A6003)) overnight at 4°C, before
centrifugation at 110*g for 15 min. The supernatant was
discarded and the pellet was washed several times. The cell
suspension was filtered through a 200 μm polyethylene
terephthalate (PET) filter with subsequent centrifugation
at 110*g for 15 min, after which the pelleted cells were re-
suspended in basal growth medium (MEM supplemented
with 10% Fetal Bovine Serum (FBS; Gibco), 1% penicillin–
streptomycin–neomycin antibiotic mixture (100×) (PSN;
Gibco), 1 ng/mL fibroblast growth factor 2 (FGF-2;
Sigma-Aldrich). The cells were seeded into T75 culture
flasks at a density of 107 per flask. 24 h later, the non-
adherent cells were removed. The medium was changed
twice a week, and subcultured prior to confluence until
the seeding of the roughness gradients. For all experi-
ments, cell passage one or two was used. 105 cells/ml cells
were seeded.
Alkaline phosphatase activity
After 2 weeks of cell culture, cells were trypsinized from
scaffolds and seeded onto the glass coverslips. The
second day, media were removed and coverslips were
washed with PBS for three times. Then cells were fixed
with 4% PFA for 2 min and washed with PBS twice.
After PBS was removed, TBST buffer (20 mM Tris–HCl
pH 7.4, 0.15 M NaCl, 0.05% Tween-20) was added. After
TBST was removed, ALP staining kit mixture (Yeasen
Biotech, Shanghai, China) was prepared and added as
instructed and incubated at room temperature for
4 hours in dark. Then the coverslips were washed with
PBS once and kept in PBS until picture capture.
For quantification of ALP activity, after cells were fixed
with 4% PFA for 2 min and washed with sterilized water
twice, mixture of ALP detection kit ( Nanjing Jiancheng
Bioengineering Institute, Nanjing, China) was added.
Optical density was measured at 405 nm using a
spectrometer.
Cell viability and proliferation
Cells were seeded at 2.0*105 cells/scaffold. One milliliter
of medium was added into each well to immerse the
scaffolds completely to be followed by culturing in an
incubator at 37°C and 5% CO2. The growth medium
used during first four days of culturing contained a 1:1
mixture of Ham’s F12 medium and Dulbecco’s modified
Eagle’s medium-low glucose (Gibco, Life Technologies),
supplemented with an antibiotic solution (100 U/ml
penicillin and 0.1 mg/ml streptomycin, Life Technologies)
and 10% fetal bovine serum (Gibco, Life Technologies).
On day 4, the growth medium was replaced with the osteo-
genic differentiation medium, which was supplemented
with 50 μg/ml ascorbic acid, 10 mmol β-glycerophosphate,
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every two days and the scaffolds were flipped during each
medium change. At days 7, 14, 21, and 28, samples were
harvested and characterized for cell differentiation analysis.
Cell proliferation was measured at 28 days post cell
seeding using 3-(4, 5-Dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) assays. MTT is a tetrazole
that can be metabolized and reduced to purple formazan
in live cells. Assays were carried out in 12-well plates:
final concentration of MTT is 0.5 mg/ml and incubated
at 37°C for 4 h and culture medium was then removed.
0.5 ml of isopropanol was then added to each well to
completely dissolve formazan crystals throughout the
PCL scaffolds. Optical density was measured at 560 nm
using a spectrometer. All data points were normalized to
the viability of PCL scaffolds without coatings.
Western blotting
Cells were lysed in MPER™ (Mammalian Protein Extrac-
tion Reagent, Thermo Scientific, Rockford, IL), which
was supplemented with cOmplete Protease Inhibitor
Cocktail tablets and PhosSTOP Phosphatase Inhibitor
Cocktail tablets (Roche, Indianapolis, IN). Protein con-
centrations of lysates were determined using the BCA
assay (Thermo Scientific, Rockford, IL) and proteins
were resolved on SDS-PAGE gels and transferred to
PVDF membrane (EMD Millipore, Billerica, MA) using
standard procedures. Membranes were blocked with
SuperBlock™ T20 (TBS) Blocking Buffer (Thermo
Scientific, Rockford, IL) and incubated overnight at 4°C
in primary antibodies of Runx2 (Cell Signaling, #8486,
1:1000), ALP (Abcam, #ab67228, 1:1000), RANKL (Cell
Signaling, #4816, 1:1000), Osteocalcin (Santa Cruz,
#sc-30044, 1:500), Osterix (Abcam, #ab22552, 1:500),
and β-actin (Sigma-Aldrich, #A1978, 1:5000). Mem-
branes were then incubated with either anti-mouse
(Cell Signaling, #7076, 1:2000) or anti-rabbit IgG (Cell
Signaling, #7074, 1:2000), HRP-linked secondary anti-
bodies and Chemiluminescented by Pierce™ ECL Western
Blotting Substrate (Thermo Scientific, Rockford, IL).
Quantification of signals on Western blots was done using
National Institutes of Health (NIH) ImageJ Imaging and
Processing Analysis Software with signaling intensity nor-
malized to β-actin.
RNA isolation, reverse transcription, and quantitative
real-time PCR (qRT-PCR)
Primers used in the present study are listed in Table 1.
All primers were synthesized by Sangon Biotech (Shang-
hai, China). Cells were first typsinized and harvested
from the scaffolds and cell pellets were stored at −80°C.
Then RNeasy kit (Qiagen) was used for total RNA ex-
traction and isolation following manufacture’s instruc-
tions. Briefly, frozen cell pellets were thawed slightly andlysed and homogenized. Ethanol was added and the
samples were transferred to to a RNeasy spin column.
The total RNA was then washed and eluted. Reverse
transcription was done with RevertAid First Strand
cDNA Synthesis Kit (Thermo Scientific, Rockford, IL)
following manufacture’s instructions. Briefly, cDNA was
synthesized using the ReveriAid M-MuLV reverse tran-
scriptase with the primers, RNase inhibitors, dNTP mix
from the kit. qRT-PCR were performed in triplicate by
Bio-Rad real-time PCR system with iQ5 SYBR Green
SuperMix (Bio-Rad) for 40 cycles at 95°C for 30 s,
53–60°C annealing temperature for 30 s, and 72°C for
60 s. Melting curve analysis was performed using
Biorad 7300 Syntem SDS software.
Scanning Electron Microscope (SEM) analysis
Field Emission Scanning Electron Microscope S-4800
(Hitachi, Japan) was used to characterize the scaffolds,
as well as the morphology and behavior of the cells grown
in the scaffolds. Prior to imaging, the cells were fixed with
2.5% glutaraldehyde and samples were dehydrated in a
graded ethanol series and sputter-coated with gold for
15-20s. All samples were analyzed at 15 kV.
Statistical analysis
Statistically significant differences between different
groups were determined by two-way ANOVA, followed
by Bonferroni post tests with P < 0.05 considered significant
(*, P < 0.05; **, P < 0.01; ***, P < 0.001) using GraphPad
Prism version 5.00 (San Diego, California) unless other-
wise specified.
Results
Morphology of uncoated and coated PCL scaffolds
Since the potential advantages of HAp, collagen, and
poly-lysine coatings have been discussed earlier, there-
fore we tried to coat PCL scaffolds with poly-lysine,
HAp, collagen or both HAp and collagen and evaluated
the morphology using SEM. Under SEM, uncoated PCL
scaffold showed a relatively smooth surface (Figure 1A).
However, it could be observed that the coated PCL scaf-
folds had surface roughness and coating materials were
successfully and uniformly deposited on the surface of
PCL scaffolds (Figure 1B-F). Of note, compared to other
PCL scaffolds, the HAp-Col and HAp PCL scaffold pre-
sented microstructure with more nanoparticles and
roughness on the surface, better mimicking the micro/
nano-structure of the natural bone and also increasing
the accessible surface for cells.
Adherence of BMSCs to the uncoated and coated PCL
scaffolds
BMSCs have been previously shown having great potential
for bone regeneration. Under certain conditions, they
Table 1 Rattus norvegicus primers used in the qRT-PCR experiments
Gene name Accession number Primer (forward) Primer (reverse)
Runt-related transcription factor 2 (Runx2) XM_001066909 5′-TAACGGTCTTCACAAATCCTC-3′ 5′-GGCGGTCAGAGAACAAACTA-3′
Osterix AY177399 5′-GCCTACTTACCCGTCTGA-3′ 5′-CTCCAGTTGCCCACTATT-3′
Alkaline phosphatase (ALP) NM_013059 5′-GCAGGATCGGAACGTCAAT-3′ 5′-ATGAGTTGGTAAGGCAGGGTC-3′
Osteocalcin J04500 5′-CACAGGGAGGTGTGTGAG-3′ 5′-TGTGCCGTCCATACTTTC-3′
Receptor activator of nuclear factor- κB ligand (RANKL) NM_057149 5′-TCGCTCTGTTCCTGTACT-3′ 5′-AGTGCTTCTGTGTCTTCG-3′
β-actin NM_031144 5′-CAGAGCAAGAGAGGCATCCT-3′ 5′-GTCATCTTTTCACGGTTGGC-3′
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over, several scaffolds have been demonstrated to promote
the growth and differentiation of BMSCs. Therefore, in
order to evaluate cytocompatibility of these uncoated and
coated PCL scaffolds, BMSCs were seeded into the scaf-
folds. After 28 days, SEM observation revealed that cells
were well attached to the poly-lysine, HAp, HAp/collagen
and collagen coated scaffold surface and grew in colonies
on the surface (Figure 2). These results indicated that all
these coated scaffolds possessed favorable cytocompatibil-
ity and provided suitable circumstances for cell growth.
Osteogenic differentiation of BMSCs growing on
uncoated and coated PCL scaffolds
Recruitment, proliferation and differentiation of BMSCs
into mature osteoblasts are the major processes ofFigure 1 Representative SEM micrographs of PCL scaffolds after coating. T
scaffolds only; B, PCL scaffolds with poly-lysine coating; C, PCL scaffolds wi
PCL scaffolds with 10 mg/ml collagen coating; F, PCL scaffolds with 30 mgosteogenesis and remain challenging in the context of
bone tissue engineering. The process of osteogenesis can
be characterized by identifying temporally regulated bone
formation markers. In BMSCs, runt-related transcription
factor 2 (Runx2), ALP, osterix and osteocalcin are the
main determinants of osteogenesis [45-48]. Runx2 and
osterix are the key transcription factors initiating and
regulating the early osteogenesis and late mineralization
of bone. The production of ALP and osteocalcin is an
early biomarker of osteogenesis. RANKL is a ligand for
osteoprotegerin and functions as a key factor for osteo-
clast differentiation and activation. Thus, these key
osteogenesis-related markers were determined to evalu-
ate the differentiating capacity of BMSCs in the scaffolds.
Gene expression analysis in the BMSCs seeded on the dif-
ferent scaffolds showed a time-dependent upregulation ofhe micrographs show the details of scaffolds after coating. A, PCL
th HAp; D, PCL scaffolds with HAp and 30 mg/ml collagen coating; E,
/ml collagen coating.
Figure 2 Representative SEM micrographs of PCL scaffolds after coating and 28 days of culturing. The micrographs show the proliferation and
spreading of BMSCs (white arrows) after 28 days in culture. A, PCL scaffolds only; B, PCL scaffolds with poly-lysine coating; C, PCL scaffolds with
HAp; D, PCL scaffolds with HAp and 30 mg/ml collagen coating; E, PCL scaffolds with 10 mg/ml collagen coating; F, PCL scaffolds with 30 mg/ml
collagen coating.
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osterix, osteocalcin and RANKL. In particular, mRNA
levels of RUNX2, osterix, and osteocalcin were signifi-
cantly higher in BMSCs seeded in HAp PCL and HAp-
Col PCL scaffolds than those seeded in uncoated PCL
scaffolds at days 21 and 28. In addition, mRNA levels of
ALP and RANKL were also significantly higher in BMSCs
seeded in HAp PCL and HAp-Col PCL scaffolds than
those seeded in uncoated PCL scaffolds at days 28
(Figure 3A-E). At the same time, mRNA expression
levels of the above markers were not significantly dif-
ferent in collagen or poly-lysine coated PCL scaffolds
from uncoated PCL scaffolds (Figure 3A-E). Additionally,
protein expression levels of RUNX2, ALP, RANKL,
Osterix and Osteocalcin of BMSCs were also much higher
in HAp-Col PCL and HAp PCL scaffolds than in un-
coated or poly-lysine and collagen coated scaffolds
(Figure 3F), indicating that both HAp-Col PCL and HAp
PCL scaffolds have favorable osteoinductive potential.
ALP activity and cell proliferation
Next, cell proliferation among groups was determined
quantitatively using MTT assay. Interestingly, results at28 days showed that collagen-coating significantly pro-
moted cell proliferation. As shown in Figure 4A, all coat-
ings significantly increased cell proliferation at days 28.
Specifically, collagen (10 Col, 30 Col), HAp-Col, and
HAp coated PCL scaffolds had higher cell proliferation
compared to viable cells in poly-lysine coated or un-
coated PCL scaffolds, suggesting that the presence of
collagen and HAp additionally stimulated BMSC prolif-
eration in coated scaffolds. As we know, collagen and
HAp are both components of natural bones and these
components may help stimulate BMSC proliferation and
provide additional surface for cell attachment according
to their SEM results (Figures 1 and 2).
Osteogenic differentiation of BMSC could show ALP
activity which can be assessed by ALP activity assays.
BMSCs in HAp-Col PCL and HAp PCL scaffolds had
remarkably higher ALP activity than those in collagen-
only coated or uncoated PCL scaffolds (Figure 4B), in-
dicating HAp and HAp-Col may help osteogenic
differentiation and stimulate osteoblast formation. Taken
together, the scaffolds with both HAp and collagen coat-
ings have the advantages of both components, and provide
the best conditions for both osteogenesis and proliferation
Figure 3 Osteogenic differentiation of BMSCs growing on scaffolds. The mRNA expression of bone tissue specific markers, including Runx2
(A), ALP (B), Osterix (C), Osteocalcin (D), RANKL (E) were evaluated during the in vitro culturing period of up to 28 days to assess osteogenic
differentiation of BMSCs by RT-qPCR at different time points. All data were normalized to the mRNA expression of the corresponding marker at
day 0 (cell seeding day). Data indicate the mean relative values calculated from six independent experiments (±S.E.). Statistically significant differences
with P < 0.05 were considered significant (*P < 0.05). F, shows a representative protein expression (as indicated) of cell lysates cultured on PCL scaffolds
only, PCL scaffolds with poly-lysine coating, PCL scaffolds with HAp, PCL scaffolds with HAp and 30 mg/ml collagen coating, PCL scaffolds with
10 mg/ml collagen coating, PCL scaffolds with 30 mg/ml collagen coating after 28 days of cell culturing.
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scaffolds, BMSC showed negative stain of ALP activity
(Figure 4C). However, after 28 days of culture in HAp-Col
PCL scaffolds, cells abundantly expressed ALP activity
and showed spread-out phenotype and were connected
with each other (Figure 4D). These morphology changes
of BMSCs before and after four-week of 3D culture againconfirmed that BMSCs successfully differentiated into
osteoblast in HAp/collagen coated PCL scaffolds. Further
SEM micrograph confirmed that in contrast to cells in un-
coated PCL scaffold, BMSCs in the HAp-Col PCL scaffold
were well attached and spread throughout the scaffold
(Figure 4E-F). In summary, our data strongly suggested
that the HAp-Col PCL scaffold, mimicking the organic
Figure 4 Cell-scaffold interactions on PCL scaffolds. BMSCs were cultured for 4 weeks in vitro. A, cell proliferation of BMSCs on PCL scaffolds with
or without coatings as indicated. Cell proliferation were determined via MTT assays. Viability of cells were normalized to the viability on PCL
scaffolds only. B, alkaline phosphates (ALP) activity after 4 weeks of BMSC culturing. Data were normalized to the ALP activity on PCL scaffolds
only. Data indicate the mean relative values calculated from six independent experiments (±S.E.). Statistically significant differences with P < 0.05
were considered significant (*P < 0.05; **P < 0.01; ***P < 0.001). C, representative BMSC image before culturing on PCL scaffolds with HAp and
30 mg/ml collagen coating. Scale bar, 10 μm. D, representative cell image after culturing on PCL scaffolds with HAp and 30 mg/ml collagen
coating. The cells have differentiated into osteoblastic cells and were stained with ALP staining kit. SEM micrographs of PCL scaffolds after
coating and 4 weeks of culturing. Scale bar, 10 μm. E, PCL scaffolds only. F, PCL scaffolds with HAp and 30 mg/ml collagen coating.
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moted BMSC attachment, proliferation and differentiation.
Discussion
Currently biodegradable polymer/bioceramic composite
was viewed as a suitable scaffold material in BTE be-
cause the addition of a polymer phase to a porous
ceramic scaffold increases the fracture toughness of thecomposite and allows the functionalization of the surface
to induce enhanced bioactivity. In this study, PCL was
chosen as the polymer layer as it is known to be
biodegradable with good biocompatibility and non-
inflammation, and has the additional advantage of
FDA approval for implant applications. HAp, was
chosen as the bioceramic layer, for the evidence that it
is bioactive. In particular, HAp material possesses
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skin, and muscles. Furthermore, HAp promotes faster
bone regeneration as well as direct bonding to regener-
ated bones without intermediate connective tissues. In
consistent with other groups, our data clearly demon-
strated that HAp-coating produced nano-featured sur-
face in Figure 1 [49,50]. Additionally, HAp-coating
subsequently facilitated BMSC homing and osteogen-
esis in vitro in Figure 2 and Figure 3, respectively. As
shown in Figure 2C, cell clustered much more densely
on HAp-coated PCL scaffolds than the scaffolds alone.
Furthermore, in Figure 3 the mRNA expression of
many biomarkers in scafffolds coated with HAp were
significantly greater than PCL scaffolds alone at day 21
and 28. All these results showed HAp-coating is favor-
able for osteoinduction and proliferation of BMSCs.
Furthermore, in our study, the method of HAp coating
is simple to perform.
To the best of our knowledge, collagen is seldomly
coated together with HAp to PCL scaffolds. In the present
study, although BMSCs showed similar osteogenesis in
HAp-only coated PCL scaffolds and HAp-col-coated PCL
scaffolds (as shown in Figure 3), combination coating of
HAp and collagen significantly enhanced BMSC survival
and proliferation (as shown in Figure 4A). As shown in
Figure 4A, all coatings significantly increased cell survival,
especially collagen coatings. As we all know, for native
bone tissue, collagen plays a dominant role in maintaining
the biological and structural integrity of ECM (extracel-
lular matrix) [51]. Studies have shown that cells bind
collagen and other ECM proteins using adhesive trans-
membrane molecules such as integrins, thus increasing
the efficiency of cell adhesion [52]. In addition, collagen
increases tissue vascularization and decreases the in-
flammatory response and macrophage and osteoclast
activity. Though HAp coatings are valuable due to their
surface chemistry and have been shown to enhance
osteoblast proliferation and differentiation, they often
suffer from high brittleness. Collagen provides the ne-
cessary environment for cell attachment and the ductile
properties of collagen also help to increase the poor
fracture toughness of HAp [52]. In fact, our results have
confirmed that the coating with both collagen and HAp
simultaneously enhanced not only BMSC proliferation
but also osteogenesis based on the advantages of the
characterics of both components of natural bones. It is
known that osseous tissue is a relatively hard and light-
weight composite material which is mostly made up of a
composite incorporating the mineral calcium phosphate
in the chemical arrangement termed calcium hydroxyl-
apatite, which gives bones their rigidity, and collagen
protein which improves fracture resistance. Therefore,
our coating of both HAp and collagen on PCL scaffolds
mimicks the biophysical and biochemical properties ofnatural bone tissue very well, and will potentially be-
come an efficient strategy to build tissue-engineered
scaffolds. Additionally, Figure 1 and 2 showed that the
PCL-HAp-collagen scaffolds had porous structures with
collagen nanofibers and HAp nanoparticles on the sur-
face. These features of such PCL scaffolds are again fa-
vorable for cell attachment and osteogenesis since the
main constituents of bone are nanometers in diameter
and native bone cells interact with nano-scale proteins
and minerals. The pore sizes are about 570 μm, which is
appropriate for bone regenerative cell migration and
infiltration.
In our results, though poly-lysine and collagen coat-
ings increased attachment and proliferation of cells,
they cannot enhance BMSC differentiation as demo-
strated by lower expression of osteogenesis-related
markers compared to HAp and HAp-Col coated scaf-
folds in Figure 3A-F and Figure 4A-B. These poly-
lysine and collagen coatings seemed to be lack of the
ability to accelerate osteogenesis BMSC differentiation.
PCL scaffolds need inorganic phase of native bone, a
necessary component, to mimick the complete matrix
for promoting BMSC differentiation. These results fur-
ther confirmed that HAp plays a pivotal role in main-
taining biocompatibility and osteoinductivity of the
scaffolds in the context of BTE.
To the best of our knowledge, the interaction between
BMSCs and PCL scaffolds coated with both HAp and
collagen haven’t been studied throughly by any other
groups yet. The incorporation of BMSCs into BTE bio-
materials is an accepted strategy for accelerated bone
formation and osteointegration during bone defect re-
pair and regeneration [9]. This present study introduces
an easy method to immobilize BMSCs on the 3D porous
PCL scaffolds and provides further evidence that modifi-
cation of 3D PCL scaffolds with both HAp and collagen
elicits specific cellular responses and improves the final
cell-biomaterial interaction. This finding suggests that
the co-coating of both HAp and collagen promotes re-
generation and that the system has potential in BTE.
Conclusions
This study demonstrates that HAp-collagen coated
PCL scaffolds possess appropriate nano-structures,
surface roughness, and nutrients, offering a favorable
environment for osteogenesis. The co-coating of collagen
and HAp in the PCL scaffolds promotes BMSC proliferation
and differetiation which play essential roles in the physio-
logical process of ostogenesis. HAp-collagen coated PCL
scaffolds take the advantages of all materials, providing
promising potential for bone tissue engineering applications.
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